A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial

Autor: Khaled M. Musallam, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Bueno, Jeevan K. Shetty, Frederik Lersch, Barbara Rosettani, Maria Domenica Domenica Cappellini

Publikováno v: Blood. 140:5358-5359

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5d2e1d1db122b43adc6b5860ff04688
https://doi.org/10.1182/blood-2022-157113

European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting

Autor: Marie-Christiane Vekemans, Elisabeth Kueenburg, Charalampia Kyriakou, Barbara Gamberi, Torben Plesner, Francesco Di Raimondo, Niels Albildgaard, Angel Ramirez Payer, Margaret Atiba-Davies, Antonia Di Micco, Pamela Bacon, Barbara Rosettani

Publikováno v: Gamberi, B, Abildgaard, N, Vekemans, M-C, Ramirez Payer, A, Kyriakou, C, Di Raimondo, F, Kueenburg, E, Di Micco, A, Rosettani, B, Atiba-Davies, M, Bacon, P & Plesner, T 2019, ' European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting ', Clinical Lymphoma, Myeloma & Leukemia, vol. 19, no. 10 Suppl., pp. e256 . https://doi.org/10.1016/j.clml.2019.09.423
Gamberi, B, Abildgaard, N, Vekemans, M-C, Ramirez Payer, A, Kyriakou, C, Di Raimondo, F, Kueenburg, E, Di Micco, A, Rosettani, B, Atiba-Davies, M, Bacon, P & Plesner, T 2019, ' European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting ', 17th International Myeloma Workshop, Boston, United States, 12/09/2019-15/09/2019 . < https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31810-5/abstract >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f3e32ef3a43994e5cc66ce8d3256a0
https://portal.findresearcher.sdu.dk/da/publications/163d971d-e1f9-4731-aa89-aadb97acef5d

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial

Autor: Barbara Gamberi, Pieter Sonneveld, Massimo Offidani, Barbara Rosettani, Meletios A. Dimopoulos, Shona Collins, Frank Bridoux, Elisabeth Kueenburg, Antonia Di Micco, Karthik Ramasamy, Matthew Streetly, Yan Li, Antonio Ardizzoia, Javier de la Rubia, Niels W.C.J. van de Donk, Katja Weisel, Pamela Bacon, Maria-Victoria Mateos

Publikováno v: Dimopoulos, M, Weisel, K, van de Donk, N W C J, Ramasamy, K, Gamberi, B, Streetly, M, Offidani, M, Bridoux, F, de la Rubia, J, Mateos, M-V, Ardizzoia, A, Kueenburg, E, Collins, S, di Micco, A, Rosettani, B, Li, Y, Bacon, P & Sonneveld, P 2018, ' Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial ', Journal of Clinical Oncology, vol. 36, no. 20, pp. 2035-2043 . https://doi.org/10.1200/JCO.2017.76.1742
JOURNAL OF CLINICAL ONCOLOGY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Journal of Clinical Oncology, 36(20), 2035-2043. American Society of Clinical Oncology
Journal of Clinical Oncology, 36(20), 2035-+. American Society of Clinical Oncology

Purpose Renal impairment (RI) limits treatment options in patients with relapsed/refractory multiple myeloma (RRMM). Here, we prospectively studied pomalidomide plus low-dose dexamethasone (LoDEX) in patients with RRMM and moderate or severe RI, incl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0c96e7dca751f8375d346c7d2917dbd
https://research.vumc.nl/en/publications/14a889b0-cfe6-41ed-8adb-e2da77db5c98

Post-Authorization Safety Study of Lenalidomide-Based vs Non–Lenalidomide-Based Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Autor: Angel Ramirez Payer, Elisabeth Kueenburg, Michele Cavo, Petra Pichler, Carsten Ziske, Barbara Rosettani, Yavuz Bilgin, Barbara Gamberi, Valerio De Stefano, Stefano Pozzi, Antonia Di Micco, Pamela Bacon

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 19:e226-e227

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5563928195ade069dae743207c4feac6
https://doi.org/10.1016/j.clml.2019.09.376

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Autor: Pamela Bacon, Elisabeth Kueenburg, Margaret Atiba-Davies, Barbara Gamberi, Barbara Rosettani, Charalampia Kyriakou, Alain Kentos, Marie-Christiane Vekemans, Torben Plesner, Francesco Di Raimondo, Angel Ramirez Payer, Antonia Di Micco, Niels Abildgaard

Publikováno v: Abildgaard, N, Vekemans, M-C, Gamberi, B, Di Raimondo, F, Ramirez Payer, A, Kyriakou, C, Kentos, A, Kueenburg, E, Di Micco, A, Rosettani, B, Bacon, P, Atiba-Davies, M & Plesner, T 2018, ' Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study ', Blood, vol. 132, no. Suppl.1, pp. 3286 . https://doi.org/10.1182/blood-2018-99-111906
Abildgaard, N, Vekemans, M-C, Gamberi, B, Di Raimondo, F, Ramirez Payer, A, Kyriakou, C, Kentos, A, Kueenburg, E, Di Micco, A, Rosettani, B, Bacon, P, Atiba-Davies, M & Plesner, T 2018, ' Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study ', American Society of Hematology: 60th Annual Meeting (ASH), San Diego, United States, 29/11/2018-04/12/2018 . < https://ash.confex.com/ash/2018/webprogram/Paper111906.html >

BACKGROUND The combination of pomalidomide (POM) and dexamethasone (DEX) for the treatment (Tx) of relapsed or refractory multiple myeloma (RRMM) in patients (pts) who have received ≥ 2 prior Tx regimens, including lenalidomide (LEN) and bortezomib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a63f22b4b5ed5634c0dbef6336cdff
https://doi.org/10.1182/blood-2018-99-111906